Market News / Story
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic…
BusinessWire ·
BusinessWire reports: Galderma ( ), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis to be presented at the 2026 Fall Clinical Dermatology Conference, taking place from October 08-11 in Las Vegas, United States. This includes a new post-hoc analysis from the ARCADIA LTE study showing that in adults and adolescents aged 12 and older who achieved an early response at Week 16 in the ARCADIA trial,…